To examine whether these proteins (i.e. CEACAM1, CEA, CEACAM6 and EPHA2) are associated with clinical outcomes in CRC patient cohorts, we screened the TCGA RNA-Seq database and evaluated 514 colon and rectal tumor samples of all stages for CEACAM1 expression in correlation with CEACAM5 (CEA), CEACAM6 and EPHA2 over a 10-year survival period. This evidence concerns the gene EPHA2 and colorectal carcinoma.